Elicio Therapeutics Secures $30M Series A Financing to Advance Proprietary Amphiphile Platform for Next-Generation Cancer Vaccines and Immunotherapies

VCBeat (WeChat ID: vcbeat) has learned that Elicio Therapeutics recently announced the completion of a $30 million Series A financing round to advance the development of its Amphiphile platform and to develop precision vaccines, immune stimulants, and cell therapies.

Elicio Therapeutics is a Cambridge, Massachusetts-based immuno-oncology company dedicated to developing precision vaccines, immune stimulants, and cell therapies by combining expertise in materials science and immunology.

It is reported that the company’s proprietary Amphiphile platform is based on pioneering research in immunomodulatory therapy by Dr. Darrell Irvine, Professor of Biological Engineering and Materials Science at the Massachusetts Institute of Technology (MIT) and an Howard Hughes Investigator at the Koch Institute for Integrative Cancer Research. This approach controls immune signaling by designing lipophilic molecules that mimic albumin’s natural targets (fatty acids), thereby delivering immunogens directly from the injection site to the lymph nodes. This powerful and flexible method can transform endogenous and engineered immune cells within the lymph nodes into a self-sustaining immune defense system, enabling durable therapeutic effects, and also assists physicians in visualizing draining lymph nodes during surgical tumor resection.

Currently, the company is designing effective cancer vaccines and immunotherapies for a range of invasive solid tumors and hematologic malignancies. Robert Connelly, CEO of Elicio Therapeutics, stated, “We are also developing cancer vaccines for pancreatic cancer, colorectal cancer, and head and neck cancers, with first-in-human trials expected to commence in the first half of 2020.” Furthermore, Elicio Therapeutics has established an extensive preclinical pipeline encompassing vaccines, adjuvants, cell-based therapeutic vaccines, and immune-stimulatory therapies.

Robert Connelly stated, “The history of early cancer vaccine development is very short. Many biotechnology companies have repeatedly hit roadblocks while developing novel immunotherapies, primarily because they were unable to target lymph nodes. Our Amphiphile platform, which combines cell therapies such as CAR-T, TILs, and NK cells, can produce highly effective cancer vaccines and adjuvants, offering patients better treatment options.”

(Compiled by: Feng Yutong)